| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2762b97ff59fc48a0007e760b586a0fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_253701b0ddf76be52966cb59eb29a77c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca78c6e754226ef1da9abf8c8862c11a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-40 |
| filingDate |
2013-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d7e2f592bbd7733375a554b1155c11f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12614f6ac3c8dbe79dbf3783c226233a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38f16257772e62b7cbc46ac59eab557d |
| publicationDate |
2017-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9795596-B2 |
| titleOfInvention |
Pharmaceutical diagnostic |
| abstract |
The present invention relates to selective cancer treatment regimes based on assaying for the presence or absence of a glutamine or a nucleic acid that encodes glutamine at position 859 of the catalytic p110α subunit of PI3K; methods for producing a transmittable form of information for predicting the responsiveness of patient to (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or a pharmaceutically acceptable salt thereof; and a kit thereof. |
| priorityDate |
2012-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |